Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study

@inproceedings{HilfikerKleiner2017BromocriptineFT,
  title={Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study},
  author={Denise Hilfiker-Kleiner and Arash Haghikia and Dominik Berliner and Jens Vogel-Claussen and Johannes Schwab and Annegret Franke and Marziel Schwarzkopf and Philipp Ehlermann and Roman Pfister and Guido Michels and Ralf Westenfeld and Verena Stangl and Ingrid Kindermann and Uwe K{\"u}hl and Christiane E. Angermann and Axel Schlitt and Dieter Fischer and Edith Katharina Podewski and Michael B{\"o}hm and Karen Sliwa and Johann Bauersachs},
  booktitle={European heart journal},
  year={2017}
}
Aims An anti-angiogenic cleaved prolactin fragment is considered causal for peripartum cardiomyopathy (PPCM). Experimental and first clinical observations suggested beneficial effects of the prolactin release inhibitor bromocriptine in PPCM. Methods and results In this multicentre trial, 63 PPCM patients with left ventricular ejection fraction (LVEF) ≤35% were randomly assigned to short-term (1W: bromocriptine, 2.5 mg, 7 days) or long-term bromocriptine treatment (8W: 5 mg for 2 weeks… CONTINUE READING
9 Citations
36 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 36 references

Similar Papers

Loading similar papers…